PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-0.08%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$2.82B
AUM Growth
+$2.82B
(-21%)
Cap. Flow
-$412M
Cap. Flow
% of AUM
-14.61%
Top 10 Holdings %
Top 10 Hldgs %
54.76%
Holding
113
New
15
Increased
15
Reduced
28
Closed
26
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$85M |
| 2 |
Insmed
INSM
|
$27.9M |
| 3 |
BBNX
Beta Bionics, Inc. Common Stock
BBNX
|
$19.5M |
| 4 |
Dyne Therapeutics
DYN
|
$18.5M |
| 5 |
Solid Biosciences
SLDB
|
$18.5M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$69.9M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$66.2M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$60M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$47.6M |
| 5 |
Insulet
PODD
|
$42.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Novavax
NVAX
$1.2B
| – | – |
0
| – | – |
|
102
Natera
NTRA
$23B
| – | – |
-125,000
| Closed | -$19.8M |
|
103
Lineage Cell Therapeutics
LCTX
$281M
| – | – |
-7,236,843
| Closed | -$3.64M |
|
104
iRhythm Technologies
IRTC
$5.67B
| – | – |
-65,153
| Closed | -$5.87M |
|
105
ImmunityBio
IBRX
$2.24B
| – | – |
-1,221,734
| Closed | -$3.13M |
|
106
Fulcrum Therapeutics
FULC
$353M
| – | – |
-238,000
| Closed | -$1.12M |
|
107
Forte Biosciences
FBRX
$138M
| – | – |
-95,742
| Closed | -$2.17M |
|
108
Edwards Lifesciences
EW
$47.7B
| – | – |
-145,000
| Closed | -$10.7M |
|
109
Crinetics Pharmaceuticals
CRNX
$3.26B
| – | – |
-184,525
| Closed | -$9.43M |
|
110
CG Oncology
CGON
$2.19B
| – | – |
-419,450
| Closed | -$12M |
|
111
Perspective Therapeutics
CATX
$251M
| – | – |
-1,190,263
| Closed | -$3.8M |
|
|
BCYC
112
Bicycle Therapeutics
BCYC
$492M
| – | – |
-197,108
| Closed | -$2.76M |
|
113
Arvinas
ARVN
$580M
| – | – |
-740,749
| Closed | -$14.2M |
|